Liaoning Cheng Da (SHA:600739) subsidiary Chengda Steel Hong Kong will invest $5 million as a limited partner in a biopharmaceutical and healthcare fund, according to a Wednesday filing with the Shanghai bourse.
The investment is equivalent to 12.95% of the Likon Venture Fund II Limited Partnership, which has so far raised $38.6 million.
The fund will invest in innovative drugs, medical devices, medical diagnostic equipment and reagents, and related service areas.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.